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Assessment of asthma severity is important for disease management. Analysis of symptoms past and 
present, and previous and actual lung function measurements (including variability) is the usual method 
of evaluation and classification of asthma disease severity and activity. However, symptoms and lung 
function alterations are the result of pathophysiological processes including inflammation in the 
bronchial wall which, in chronic phases, precedes the clinical measurements, and are risk factors for 
disease progression and worsening. Tools for more precise determination of asthma disease processes in 
the airway wall would be of importance for prophylactic intervention to avoid chronic damage to the 
airways and acute worsenings to occur. 
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Introduction 
Monitoring of bronchial asthma should live up to the 
expectations of treatment for the individual patients 
(1). The desired treatment outcomes are generally 
regarded as: elimination of symptoms; improvement 
and, hopefully, normalization of lung function to the 
individual’s personal best; reduction and elimination 
the occurrence of exacerbations; and achievment of 
the above with little or no adverse effects from 
intervention and treatments. 
A pre-requisite for reaching treatment goals is good 
patient education that enables the patient to under- 
stand the asthmatic disease process, and what governs 
worsenings, stabilization and improvements of the 
disease (2). A patient must have a thorough under- 
standing of the treatment offered. The patient must be 
able to assess symptoms and have proper equipment 
for measuring lung function at home (3). In many 
cases, this will involve different degrees of altered 
behaviour of the patient’s way of life, including smok- 
ing cessation and allergen avoidance measures (4). 
The health professional taking care of the patient 
must be able to assess the disease severity (5), investi- 
gate the cause of the disease, and offer guidance and 
optimum treatment to the patient (1,2). Inadequate 
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assessment of the severity of asthma may be a cause of 
undertreatment (5). In a survey of paediatricians and 
family physicians, concerning questions most com- 
monly asked of asthmatic patients about their clinical 
progress during a typical office visit, a substantial 
number failed to include important inquiries concern- 
ing the child’s functional status (7). As a consequence, 
in the majority of patients with severe and dis- 
abling symptoms receiving care by paediatricians, 
family practice or emergency-room physicians, in- 
haled adrenergic agents had not been prescribed. In 
contrast, allergists and pulmonologists prescribe 
adrenergic agents more appropriately. 
Proper assessment should include not only evalu- 
ation of objective measurements, such as pulmonary 
function, but also the effect of symptoms on the 
quality of the child’s life. It is, therefore, important to: 
(i) promote the continuance of education of primary- 
care physicians; (ii) encourage appropriate referrals 
to qualified subspecialists; (iii) enhance education of 
patients and parents; and (iv) plan the management of 
asthma from the perspective of the ‘whole patient’ (8). 
The present recommended method for optimum 
assessment involves monitoring of symptoms and 
lung function. 
Symptoms 
Symptoms can be monitored by asking questions 
about the following: breakthrough cough and 
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wheezing with viral infections, physical activities, 
school/work absences, quality of sleep, morning 
cough and chest tightness requiring treatment, 
number of acute episodes, how often and for how 
long are P-agonists used, how frequently are P-agonist 
inhalers renewed, and medication side-effects. It is 
becoming increasingly clear that frequent acute epi- 
sodes of asthma requiring emergency room visits 
represent (excluding the most severely affected sub- 
jects) a failure of ambulatory treatment. Further, 
aggressive management of the acute exacerbation 
often aborts the episode and prevents its further 
progression. The theory that the best time to treat a 
severe attack of asthma is ‘2 days before it happens’ 
should be stressed to primary-care family physicians. 
With regard to this, it is well known that an overt 
episode of asthma is often preceded by a variety of 
prodromal symptoms, some of which are not related 
to the respiratory system. A study has shown that 
prodromal symptoms are present 6 h or more before 
an acute episode in 71% of asthmatic children; the 
other 29% had a rapid evolution of symptoms that led 
to overt episodes of asthma within 6 h (9). In the 
same study, the majority of patients with prodromal 
features showed the same prodromal symptoms, 
while only a minority of patients showed a variable 
number of prodromal symptoms in each subsequent 
episode of asthma. The determination of these dif- 
ferent features has practical consequences in the 
therapeutic strategy. For example, the recognition of 
prodromal symptoms may lead to an earlier introduc- 
tion of treatment, thus avoiding or abbreviating some 
episodes of asthma. Also, in children with acute onset 
of asthma without prodromal symptoms, a more 
extensive prophylactic treatment may be considered. 
Lung Function 
Airflow obstruction in asthma is, by definition, vari- 
able and a patient will frequently be in a remission 
phase in the clinic. It is, therefore, important to 
measure lung function over a period of time in order 
to perform a diagnosis, or to assess the response to 
treatment and to dictate therapy. Airway narrowing 
is the characteristic physiological abnormality both in 
acute and chronic asthma. In cases of acute exacer- 
bation of asthma, the severity should be assessed 
carefully, evaluating the degree of bronchoconstric- 
tion with measurement of peak expiratory flow 
(PEF), as well as with clinical assessment of the use 
of accessory muscles and monitoring of pulse and 
respiratory rate. 
In an emergency situation, a rough indication of 
gross change is all that is required since it provides an 
objective assessment of the response to &agonists, 
whether hospital admission is indicated and how 
aggressive subsequent therapy should be (2). Follow- 
ing treatment, the child should be evaluated for 
improvement using PEF and this may influence the 
timing of discharge. 
As PEF measurements in young children cannot 
always be performed reliably, other parameters of 
respiratory failure, such as ability to suckle or feed, or 
chest retractions, should be sought. Furthermore, the 
presence of cyanosis and the quality of the infant’s 
cry should be considered in the small infant. 
In chronic asthma, it is possible that the incidence 
of airway narrowing may be much higher than indi- 
cated by symptoms or intermittent lung function 
measurement. In these conditions, twice daily moni- 
toring of peak flow has been suggested in order to 
monitor the severity of disease and response to 
therapy (1,2). 
Peak expiratory flow measurement is the proposed 
minimum objective parameter for monitoring bron- 
chial asthma. However, readings obtained on mini- 
flow meters must be interpreted with caution as they 
may be inaccurate. It has been shown that miniflow 
meters read low flows quite well, over-read flows 
between 200 and 400 1 min - ‘, which is the usual 
paediatric range, and under-read higher flows (10). 
Furthermore, since readings vary between different 
brands of flow meters, in order to make comparisons 
over time it is desirable for the patient to always use 
the same meter (11). A system of PEF rate zones 
adapted to a traffic light system, i.e. green, yellow and 
red, has been suggested to help patients manage their 
asthma at home (12-14) (Table 1). 
Patients’ and parents’ perception of airways 
obstruction in their children may not be reliable (15). 
Therefore, measuring PEF at home should provide 
more objective evidence of airways obstruction from 
day to day. Such monitoring is not possible for most 
patients during prolonged periods, but can be recom- 
mended in newly diagnosed cases to obtain an opti- 
mum baseline for evaluation of disease severity. 
Detailed recordings are also recommended in relation 
to alterations in medication and in the period after an 
exacerbation. An indiscriminate prescription of peak 
flow meters in asthmatics with infrequent episodic 
problems has to be avoided. Such patients derive no 
benefit from continuous peak flow monitoring, and 
twice daily recording in a relatively asymptomatic 
patient may be a greater burden to the patient than 
the disease. 
Frequent lung function monitoring, however, is an 
essential feature in patients with severe disease and in 
those with poor perception of symptoms. A recent 
study has demonstrated that PEF monitoring is 
of greater use in assessing asthma severity during 
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TABLE 1. Evaluation of bronchoconstriction by peak expiratory flow rate 
Percentage of 
personal best Indication 
80-100 (Green) No asthma symptoms. 
Follow the routine treatment. 
50-80 (Yellow) 
Long-term stability may suggest a reduction in medication. 
Possible acute exacerbation or inadequate control of overall asthma. 
The current therapy may need to be increased or other medications 
may need to be added. 
~50 (Red) 
&-agonists and possibly oral corticosteroids are indicated. 
Asthma alert. 
Bronchodilator therapy along with the early introduction of 
corticosteroids is necessary. A comprehensive plan to return to 
stability is essential. 
symptoms than detecting asthma in asymptomatic 
patients (16). 
Twice daily monitoring (morning and evening) of 
PEF has been suggested in order to evaluate 
increased bronchial lability. The percent lability can 
be calculated for each day by expressing the difference 
in PEF divided by the mean in PEF as a percentage 
(17). A 20% lability has been suggested as a useful 
screening test for asthma in adults (18). However, this 
index of lability was found to be an insensitive 
diagnostic test for asthma in children, since 40% of 
the children were not ‘recognized’ by the test (19). 
Blood Gas Analysis 
Blood gas analysis is not essential in all patients with 
severe acute asthma, provided that the patient is not 
desperately ill, and responds to initial therapy satis- 
factorily. In such a case, the clinical assessment 
combined with PEF measurement in patients over the 
age of 6 or 7 years will usually be adequate to judge 
progress. Since functional evaluation in infants is 
more difficult, and because hypoxaemia will develop 
earlier in infants than in adults, oxygen saturation 
(measured by pulse oximetry) should be determined 
in all asthmatic infants. Decreased oxygen saturation 
(below 0.93) is often an early sign of moderate to 
severe bronchoconstriction. 
Bronchial Hyper-responsiveness 
Bronchial hyper-responsiveness (BHR) is a feature of 
symptomatic asthma. There is generally a positive 
relationship between the degree of airway hyper- 
responsiveness and the severity of the patient’s 
asthma (20). However, BHR can be present in asymp- 
tomatic people and in patients with chronic airflow 
limitations associated with a different pathogenesis, 
such as cigarette smoking, chronic bronchitis and 
cystic fibrosis (21). There is a considerable overlap in 
results between asthmatics of differing severity and in 
non-asthmatics who have other respiratory problems. 
Measurement of PC,, or PD,, methacholine and 
histamine (respectively, the concentration or dose of 
methacholine and histamine that cause a 20% fall 
in PEF or FEV,) seems to be of limited value in 
monitoring disease because of low specificity (22). 
Exercise challenge responses are, however, more 
specific and can be used to document exercise- 
induced bronchoconstriction (23). The use of differ- 
ent agents such as adenosine may provide greater 
sensitivity and specificity (24) 
Markers of Airway Inflammation 
The current appreciation of the inflammatory nature 
of asthma necessitates the development of new tech- 
niques to monitor the inflammation that occurs in the 
asthmatic patient, as well as the identification of 
the inflammatory cells and their mediators within 
the lung. 
Research in the last decade has shown that mast 
cells, eosinophils and T-lymphocytes of Th, pheno- 
type play a pivotal role in airway inflammation, and 
that inflammation is principally mediated through 
cytokines released by those cells (25). 
Eosinophils play a key role in the late asthmatic 
reaction. After an antigen challenge, there is a 
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recruitment of eosinophils from the circulation into 
the airway wall (26). Within the airways, the eosi- 
nophils release major basic protein (MBP), eosinophil 
cationic protein (ECP), eosinophil derived neurotoxin 
(EDN) and eosinophil peroxidase (EPO). 
Studies have shown that MBP levels in sputum are 
increased during exacerbation of asthma (27). Simi- 
larly serum levels of ECP have been shown to be 
elevated during asthma exacerbations and following 
allergen exposure (28,29). Therefore, serum levels of 
ECP may be used under special circumstances to 
assess the degree of eosinophilic inflammation. How- 
ever, the rigorous sampling requirements with separ- 
ation of serum between 1 and 2 h after sampling 
renders the test difficult in routine clinical practice. 
The value of sputum eosinophils is currently being 
evaluated in many asthma centres, this may be used 
as a monitoring device in the future. Recently, it has 
been shown, in asthmatic children allergic to house 
dust mite, that a regimen of strict antigen avoidance 
is associated with a reduction of eosinophils in the 
sputum, along with an improvement in BHR (30). 
Measurement of mast cell mediators, such as 
PGD,, tryptase, histamine and the sulphidopeptide 
leukotrienes such as LTC, D, and E,, as well as 
lymphocytes, cytokines or soluble receptors in bron- 
choalveolar lavage and blood, is still experimental, 
and has no role in clinical daily monitoring of the 
disease (3 1). 
At present, ECP seems to be the most clinically 
relevant marker of inflammation in allergic diseases 
(32). However, the potential utility of monitoring 
ECP in asthmatics remains to be further investigated. 
Evaluation of the bronchial inflammatory reaction 
degree can also be explored by measurement of NO, 
H,O, or leukotrienes in exhaled air. In normal 
human airways, the production of nitric oxide (NO) is 
restricted to the nasal mucosa. In mild asthmatics, the 
level of exhaled NO during oral breathing is increased 
2-3-fold indicating the involvement of lower airways, 
particularly terminal and respiratory bronchioles 
(33). The NO seems to be derived from epithelial 
cells, macrophages and infiltrating inflammatory cells 
(34). A high concentration of NO, produced by 
inducible NO synthase in epithelial cells or inflamma- 
tory cells; may suppress the activity of the constitutive 
NO synthase and ultimately cause airway constriction 
(35). 
At present, however, the procedures to measure 
exhaled NO are at an experimental level. They are 
limited by the cost of the apparatus and the stan- 
dardization of the procedure, which may limit their 
widespread use. The performance of bronchoscopy 
with bronchoalveolar lavage (BAL) and bronchial 
biopsies are very time consuming and can only be 
applied on an experimental basis. Bronchoscopy and 
BAL are not part of routine clinical practice in 
children, and should be used where there is the need 
to exclude other causes of wheezing (36). 
Other Modalities 
Many physicians now recognize the importance of 
incorporating an assessment of health-related quality 
of life into clinical studies. Conventional clinical 
measures, such as pulmonary function studies or 
evaluation of BHR, provide useful information con- 
cerning the status of the airways but they hardly give 
any information concerning the physical, emotional 
and social impairments of the patients. In order to 
have a complete picture of a patients’ health status, it 
is important to measure both conventional clinical 
indices and also to perform disease-specific quality- 
of-life questionnaires (37). The questionnaires have 
been developed and validated in patient populations, 
and there is now considerable evidence to show that 
they can provide valid estimates of impaired health in 
asthmatic patients (38). However, although assess- 
ment of quality of life may be used in explorative 
clinical trials, at present, these investigations are time 
consuming and cannot be used on a wide-scale basis. 
Also, monitoring of compliance (39) and side-effects 
of the disease itself and of the treatment (growth in 
children) is important (40). 
Consultations 
To improve the quality of scheduled contacts with 
doctors and patients, both parties should prepare 
for the consultation I-2 weeks beforehand to derive 
maximum benefit (41). At the consultation, detailed 
information of the symptoms during the last 1-2 
weeks should be obtained in a standardized matter 
and evaluated. Detailed information of rescue 
&-agonist consumption and the daily prescribed 
medication used should be obtained. Spirometry 
should be performed and the patients should 
ask whatever questions they may have of the doctor 
(42). 
Summary 
In the evaluation of asthma, monitoring pro- 
cedures must be tailored to assess whether 
treatment goals are reached. Therefore, the assess- 
ment primarily includes: (i) specific and detailed 
evaluation of symptoms; (ii) standardized measure- 
ment of lung function; (iii) in certain instances, 
measurement of parameters to evaluate bronchial 
inflammation and reactivity; and (iv) measurement of 
compliance, side-effects and quality of life. 
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